Our findings are consistent with observational studies and studies applying a polygenic risk score approach and further support an effect of BMI on risk of MS (4–6, 8–12) and of BMI on IL-6 levels (19, 44–47). This evidence concerns the gene IL6 and myeloid sarcoma.